<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005520</url>
  </required_header>
  <id_info>
    <org_study_id>05-004017</org_study_id>
    <secondary_id>R01HL053330</secondary_id>
    <secondary_id>R01HL074735</secondary_id>
    <nct_id>NCT00005520</nct_id>
  </id_info>
  <brief_title>Genetic Epidemiology of Responses to Antihypertensives</brief_title>
  <acronym>GERA</acronym>
  <official_title>Genetic Epidemiology of Responses to Antihypertensives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether measured variation in genes coding for components of vasoconstriction
      and volume regulating systems predict interindividual differences in blood pressure response
      to therapy with a thiazide diuretic, hydrochlorothiazide, or an angiotensin II receptor
      blocker, candesartan, in hypertensive African-Americans (N=300 treated with each drug) and in
      hypertensive European Americans (N=300 treated with each drug).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      Essential hypertension is a common disorder that contributes to morbidity, mortality, and
      cost of health care, especially among African-Americans. Although a single-drug therapy is
      commonly prescribed for treatment of hypertension, blood pressure levels are controlled in
      some individuals but not in others. The study has the potential to identify genes
      contributing to the etiology of interindividual differences in blood pressure response to
      diuretic therapy in African-Americans and European Americans.

      DESIGN NARRATIVE:

      Hypertensive adults were treated with the diuretic hydrochlorothiazide, 25 mg/day, for four
      weeks; or with the angiotensin II receptor blocker candesartan, 16 mg/day for 2 weeks
      followed by 32 mg/day for 4 weeks. Interindividual variations in blood pressure responses and
      in candidate genes coding for components of systems regulating vasoconstriction and volume
      were measured. In addition, a panel of 500,000 single nucleotide polymorphisms genome-wide
      was measured in subsets of the most extreme responders and nonresponders to each drug for
      genome-wide association of analyses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1997</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>4 weeks for hydrochlorothiazide; 6 weeks for candesartan</time_frame>
    <description>The blood pressure response to antihypertensive drug therapy was defined by the difference between blood pressure levels prior to and at the end of drug therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse metabolic changes</measure>
    <time_frame>4 weeks for hydrochlorothiazide only</time_frame>
    <description>Potentially adverse metabolic changes in response to hydrochlorothiazide include changes in fasting serum glucose and insulin; serum potassium; serum lipids (triglycerides, HDL-cholesterol, total cholesterol); and serum uric acid.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">1200</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Diseases</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>African American hydrochlorothiazide</arm_group_label>
    <description>300 African American hypertensives were treated with hydrochlorothiazide 25 mg daily for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>European American hydrochlorothiazide</arm_group_label>
    <description>300 European American hypertensives were treated with hydrochlorothiazide 25 mg daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>African American candesartan</arm_group_label>
    <description>300 African American hypertensives were treated with candesartan 16 mg daily for 2 weeks followed by 32 mg daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>European American candesartan</arm_group_label>
    <description>300 European American hypertensives were treated with candesartan 16 mg daily for 2 weeks followed by 32 mg daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <arm_group_label>African American hydrochlorothiazide</arm_group_label>
    <arm_group_label>European American hydrochlorothiazide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan</intervention_name>
    <arm_group_label>African American candesartan</arm_group_label>
    <arm_group_label>European American candesartan</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma, buffy coat, urine.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult African American men and women with previously diagnosed primary hypertension were
        recruited from Atlanta, Georgia; and adult European American man and women with previously
        diagnosed primary hypertension were recruited from Rochester, Minnesota.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Primary (essential) hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen T. Turner, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension. 2001 Feb;37(2 Pt 2):739-43.</citation>
    <PMID>11230366</PMID>
  </reference>
  <reference>
    <citation>Turner ST, Boerwinkle E. Genetics of hypertension, target-organ complications, and response to therapy. Circulation. 2000 Nov 14;102(20 Suppl 4):IV40-5. Review.</citation>
    <PMID>11080130</PMID>
  </reference>
  <reference>
    <citation>Turner ST, Schwartz GL, Chapman AB, Hall WD, Boerwinkle E. Antihypertensive pharmacogenetics: getting the right drug into the right patient. J Hypertens. 2001 Jan;19(1):1-11. Review.</citation>
    <PMID>11204288</PMID>
  </reference>
  <reference>
    <citation>Montori VM, Schwartz GL, Chapman AB, Boerwinkle E, Turner ST. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc. 2001 Sep;76(9):877-82.</citation>
    <PMID>11560297</PMID>
  </reference>
  <reference>
    <citation>Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. Use of gene markers to guide antihypertensive therapy. Curr Hypertens Rep. 2001 Oct;3(5):410-5. Review.</citation>
    <PMID>11551376</PMID>
  </reference>
  <reference>
    <citation>Schwartz GL, Chapman AB, Boerwinkle E, Kisabeth RM, Turner ST. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem. 2002 Nov;48(11):1919-23.</citation>
    <PMID>12406976</PMID>
  </reference>
  <reference>
    <citation>Garovic VD, Joyner MJ, Dietz NM, Boerwinkle E, Turner ST. Beta(2)-adrenergic receptor polymorphism and nitric oxide-dependent forearm blood flow responses to isoproterenol in humans. J Physiol. 2003 Jan 15;546(Pt 2):583-9.</citation>
    <PMID>12527744</PMID>
  </reference>
  <reference>
    <citation>Turner ST, Boerwinkle E. Genetics of blood pressure, hypertensive complications, and antihypertensive drug responses. Pharmacogenomics. 2003 Jan;4(1):53-65. Review.</citation>
    <PMID>12517286</PMID>
  </reference>
  <reference>
    <citation>Schwartz GL, Turner ST. Pharmacogenetics of antihypertensive drug responses. Am J Pharmacogenomics. 2004;4(3):151-60. Review.</citation>
    <PMID>15174896</PMID>
  </reference>
  <reference>
    <citation>Frazier L, Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic. Pharmacogenomics J. 2004;4(1):17-23.</citation>
    <PMID>14735111</PMID>
  </reference>
  <reference>
    <citation>Turner ST, Chapman AB, Schwartz GL, Boerwinkle E. Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens. 2003 Oct;16(10):834-9.</citation>
    <PMID>14553962</PMID>
  </reference>
  <reference>
    <citation>Finkielman JD, Schwartz GL, Chapman AB, Boerwinkle E, Turner ST. Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazide. Am J Hypertens. 2005 Mar;18(3):398-402.</citation>
    <PMID>15797660</PMID>
  </reference>
  <reference>
    <citation>Turner ST, Schwartz GL. Gene markers and antihypertensive therapy. Curr Hypertens Rep. 2005 Feb;7(1):21-30. Review.</citation>
    <PMID>15683583</PMID>
  </reference>
  <reference>
    <citation>Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem. 2005 Feb;51(2):386-94.</citation>
    <PMID>15681560</PMID>
  </reference>
  <reference>
    <citation>Maitland-van der Zee AH, Turner ST, Schwartz GL, Chapman AB, Klungel OH, Boerwinkle E. A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide. Pharmacogenet Genomics. 2005 May;15(5):287-93.</citation>
    <PMID>15864129</PMID>
  </reference>
  <results_reference>
    <citation>Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-Dehoff RM, Boerwinkle E, Johnson JA, Bailey KR. Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response. J Transl Med. 2012 Mar 13;10:47. doi: 10.1186/1479-5876-10-47.</citation>
    <PMID>22413836</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2000</study_first_submitted>
  <study_first_submitted_qc>May 25, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2000</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Stephen T. Turner</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Pharmacogenetics</keyword>
  <keyword>Hydrochlorothiazide</keyword>
  <keyword>Candesartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

